Literature DB >> 35087212

Survival benefit with second-line combination in endometrial cancer.

Diana Romero1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35087212     DOI: 10.1038/s41571-022-00604-6

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Authors:  Vicky Makker; Nicoletta Colombo; Antonio Casado Herráez; Alessandro D Santin; Emeline Colomba; David S Miller; Keiichi Fujiwara; Sandro Pignata; Sally Baron-Hay; Isabelle Ray-Coquard; Ronnie Shapira-Frommer; Kimio Ushijima; Jun Sakata; Kan Yonemori; Yong Man Kim; Eva M Guerra; Ulus A Sanli; Mary M McCormack; Alan D Smith; Stephen Keefe; Steven Bird; Lea Dutta; Robert J Orlowski; Domenica Lorusso
Journal:  N Engl J Med       Date:  2022-01-19       Impact factor: 91.245

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.